NEW YORK (TheStreet) -- Dyax Corp (DYAX) shares are jumping, up 25% to $8.25, on Tuesday after rival Biocryst (BCRX) reported positive findings in the clinical trial for its hereditary angioedema (HAE) drug BCX416.
Investors have reacted positively to the news as it bodes well for Dyax's alternative HAE treatment DX-2930, which is currently being developed as a prophylactic HAE treatment.
Must Read: Warren Buffett's 25 Favorite Stocks
